Research led by Dr. Reuben S. Harris at UT Health San Antonio has revealed critical insights into the role of apolipoprotein B mRNA-editing enzymes, commonly known as APOBECs, in cancer development. These enzymes, which typically serve to protect the body from viral infections, can become detrimental when dysregulated in cancerous cells.
Dr. Harris, who chairs the Department of Biochemistry and Structural Biology, explained that while APOBECs are designed to mutate viral DNA to prevent infection, they can inadvertently inflict damage on the human genome during cancer progression. “In cancer, the good guys can become villains that do catastrophic damage,” Dr. Harris stated. This duality highlights an urgent need for targeted therapeutic strategies.
Targeting APOBECs in Cancer Treatment
The research proposes that during standard cancer treatments, such as surgical resection, there exists a critical opportunity to mitigate the harmful effects of APOBECs. Dr. Harris suggested that after the removal of an APOBEC-positive tumor, it may be possible to inhibit these enzymes to lower the risk of cancer recurrence or the development of drug-resistant mutations.
“If we can stop that, we can make all of these adverse events much less likely to happen,” he said. This innovative approach aims to harness the immune system’s natural mechanisms while minimizing the collateral damage typically associated with cancer therapies.
The findings were part of a program that aired on April 7, 2024, as part of an ongoing collaboration between Texas Public Radio (TPR) and The University of Texas Health Science Center at San Antonio. This partnership seeks to illuminate how scientific advancements in San Antonio are influencing medical practices worldwide.
The implications of this research are substantial, as they offer a pathway to improve outcomes for cancer patients. With more research, the hope is to develop therapies that can effectively regulate APOBEC activity, thereby enhancing the effectiveness of existing cancer treatments and reducing the likelihood of adverse outcomes.
As scientists continue to explore the complexities of the immune response in cancer, the work of Dr. Harris and his team stands out as a promising avenue for future investigation. By transforming these immune enzymes from potential adversaries into allies, researchers aim to reshape the landscape of cancer treatment.
